openPR Logo
Press release

Global Kaposi Sarcoma Market Trends & Industry Forecast by 2016 - 2024

09-04-2017 08:12 AM CET | Health & Medicine

Press release from: TMR - Healthcare

Global Kaposi Sarcoma Market Trends & Industry Forecast by 2016 -

Kaposi Sarcoma Market: Snapshot

Kaposi sarcoma (KS) refers to a type of cancer that develops from the cells lining blood vessels or lymph nodes. The cancer usually appears as tumors on mucosal surfaces or on the skin, but can also develop in body parts such as the digestive tract, or the lungs. The abnormal KS cells cause brown, purple, or red blotches on the skin, called lesions.

The global Kaposi sarcoma market features a rising number of regional vendors commanding prominent shares in their respective regional territories. Owing to the looming patent expiries of several blockbuster drugs, the market is expected to witness the entry of several new companies producing generics. The situation also presents immense growth opportunities for leading companies with new drug formulations in the next few years.

Transparency Market Research states that the global Kaposi sarcoma market will exhibit a modest 2.2% CAGR over the period between 2016 and 2024, rising from a valuation of US$118.5 mn in 2015 to US$143.2 mn by 2024.

Obtain Report Details @
http://www.transparencymarketresearch.com/kaposis-sarcoma-market.html

Chemotherapy Continues to Remain Most Preferred Course of Treatment despite High Cost

The key treatment methods for Kaposi sarcoma include immunotherapy, chemotherapy, and antiretroviral therapy. Of these, the segment of antiretroviral therapy emerged at the leading segment owing to the high incidence rate of AIDS-related Kaposi sarcoma. The segment will continue to grow at an encouraging pace in the next few years as well.

Over the report’s forecast period, however, the segment of chemotherapy is expected to exhibit growth at the most promising pace, chiefly owing to the high treatment cost and the high preference given to the treatment method by immunocompetent patients. Some of the most popular chemotherapy drugs in the market are vincristine, docetaxel, paclitaxel, bleomicin, daunorubicin, and liposomal doxorubicin. Although the high preference to this treatment method, its high cost could emerge as a key deterrent to patient population across some regions, especially across developing and less developed economies across Asia Pacific and Africa, limiting its growth prospects.

North America to Retain Dominance in Global Market despite a Low Rate of Prevalence of Kaposi Sarcoma

From a geographical standpoint, North America is presently the leading contributor of revenue to the global Kaposi sarcoma market. The region holds a leading position in the global market owing to the presence of some of the world’s leading vendors in the field and the rising costs of drugs. The North America market for Kaposi sarcoma also benefits from the high rate of diagnosis of the condition and the easy availability of drugs. The region features a low incidence rate of the disease but has been witnessing a shortage in supply of drugs required for its treatment, leading to a wide demand-supply gap and subsequently significant scope of growth.

Over the report’s forecast period, the market is expected to witness the most promising rate of growth in the Middle East and Africa region. The region is expected to lead to the heightened demand for Kaposi sarcoma drugs owing to the high rate of incidence of the disease. The high rate of prevalence of HIV/AIDS is and thus the increased prevalence of AIDS induced Kaposi sarcoma in Eastern Africa is also a key driving factor, along with the fact that awareness among people is low.

Some of the leading players operating in the immensely consolidated vendor landscape of the global Kaposi sarcoma market are Johnson & Johnson, Merck & Co., Inc., Bristol Myers Squibb, Hoffman-La Roche, Inc., Pfizer, Inc., GlaxoSmithKline plc, and Eli Lilly and Co.

Fill the form for an exclusive sample of this report @
http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=3354

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who us e proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Contact

Transparency Market Research
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com
Browse market research blog:
https://tmrresearch.blogspot.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global Kaposi Sarcoma Market Trends & Industry Forecast by 2016 - 2024 here

News-ID: 696167 • Views: 179

More Releases from TMR - Healthcare

Clinical Trial Management System (CTMS) Market : Projection of Each Major Segmen …
With companies long having realized that the best way to remain competitive in the pharmaceutical industry is by ploughing back of profits into R&D projects, the demand for clinical trial management systems is expected to see an uptick. While this will help impel the market greatly in the coming years, what also needs to be taken into consideration that the cost of implementing such a system may deter investment decisions. The
Electronic Health Records Market : Industry Analysis and Detailed Profiles of to …
The global market for electronic health record (EHR) features a largely fragmented vendor landscape, with the presence of a large number of small and large players and the top five companies cumulatively accounting for a nearly 44% of the overall market in 2016. Leading vendors in the global EHR market are adopting inorganic growth strategies such as mergers and acquisitions to expand their reach across high-growth potential regional markets, consolidate
Fuel Oil Market Intelligence Report Offers Growth Prospects
The global transportation industry has been growing at a significant pace since the past decade. Companies operating in the transportation industry are the largest consumers of the fuel oil. Apart from this, fuel oil also finds application in the petrochemical industry and petroleum refineries. The building materials industry is also on the rise since many years. The demand for fuel oil is expected to increase from the building materials industry.
Thermoset Resin Market Global Industry Analysis, Trends and Forecast, 2016 - 202 …
The global composite industry has been expanding significantly in terms of production, technological advancements, and developments. Thermoset resin plays a vital role in the composite industry. Thermoset resins are used extensively in the manufacture of composites; these resins are employed in the fabrication of products for end-use industries such as aerospace, automotive, sporting goods, construction, electronics, and wind energy. The thermoset resin market can be segmented into six resin types:

All 5 Releases


More Releases for Kaposi

Kaposi Sarcoma Treatment Market Drivers
Increasing number of patients undergoing organ transplant procedures is the leading cause for growth of the Kaposi sarcoma treatment market, as patients undergoing organ transplants are highly susceptible to this cancer. For instance, according to the National Kidney Foundation (NKF), in 2014, 17,107 kidney transplants took place in the U.S. Among which, 11,570 came from deceased donors and 5,537 came from living donors. Furthermore, increasing incidence of HIV/AIDS-associated Kaposi sarcoma
Kaposi Sarcoma Treatment Market Competitive Landscape
Kaposi sarcoma is a malignant tumor disease majorly associated with skin, mucous membranes, lymph nodes, and other organs. Kaposi sarcoma causes lesions to grow in the skin, in the mucous membranes lining the mouth, nose, and throat, lymph nodes, and other organs. Human herpesvirus-8 (HHV-8) is majorly found in the lesion of all patients suffering from Kaposi sarcoma. However, patients with weakened immune systems by Acquired Immune Deficiency Syndrome (AIDS)
Kaposi Sarcoma Market Analysis & Trends 2024
The global market for Kaposi sarcoma is projected to expand at a modest 2.2% CAGR from 2016 to 2024, with the opportunity in the market rising from US$118.5 mn in 2015 to be worth US$143.2 mn by the end of the forecast period. Hospitals formed the leading distribution channel in 2015, generating over US$40 mn revenue that year. The segment is also slated emerge as the fastest growing segment in
Kaposi Sarcoma Market Research Report | Market Growth Analysis 2024
The Global Kaposi Sarcoma (KS) Market is immensely consolidated and the top two players, namely Johnson & Johnson and Merck & Co. Inc. accounted for almost 50% of the overall market in 2015. The contribution of domestic players such as Sun Pharmaceutical Industries Limited is presented low. However, Transparency Market Research predicts that the contribution of these companies will increase during the forecast period owing to the patent expiry of
Kaposi Sarcoma Market Research Report 2024
The global Kaposi sarcoma (KS) market is immensely consolidated and the top two players, namely Johnson & Johnson and Merck & Co. Inc. accounted for almost 50% of the overall market in 2015. The contribution of domestic players such as Sun Pharmaceutical Industries Limited is presented low. However, Transparency Market Research predicts that the contribution of these companies will increase during the forecast period owing to the patent expiry of
Kaposi Sarcoma Market: North America Leads Global Market despite Lower Incidence …
According to the U.S. Centers for Disease Control and Prevention, Kaposi sarcoma (KS) is considered to be an AIDS-defining disease, indicating that patients with KS go on to develop AIDS. The incidence of Kaposi sarcoma was reportedly high in homosexual men with HIV. The market for Kaposi sarcoma is characterized by the increasing number of domestic players playing an important role in their respective regional markets. Given the patent expiry of